Kewaunee Scientific Corp /De/KEQU

Kewaunee Scientific Corporation doesn’t just sell laboratory casework; it occupies the quiet corner of every science department that can’t afford a new building but still needs brand-new benches. The 10-K filed on 30 April 2026 reports $282 million in revenue from contracts with customers, a figure that sounds impressive until you notice that net cash from operating activities was only $18.6 million. The company’s cash pile sits at $9.9 million, while liabilities weigh in at $101.5 million, leaving shareholders with $74.7 million of equity to cover the gap. Diluted earnings per share of $3.22 on 3.0 million shares feel like a victory lap compared with the balance-sheet tightrope beneath.

What Kewaunee actually makes are steel casework systems, chemical fume hoods, and epoxy resin countertops, all manufactured in Statesville, North Carolina. The official product pages promise durability, chemical resistance, heat resistance, and scratch resistance-qualities that would reassure any lab manager until you compare them with the $30.5 million of inventory that the company shrank by $2.3 million over the year. Either the resin is disappearing into labs faster than the marketing copy suggests, or the warehouse audit missed a few crates.

The 2026 proxy filings show that the Nominating and Corporate Governance Committee Charter on the company’s website outlines a process for identifying board candidates, while insiders filed Form 4 notices in early July 2026 indicating sales within days of the 10-K release. Research and development expense for the year was $898,000, or roughly 0.32% of revenue. The board approved an equity compensation plan in July 2026, a move that looks like an invitation to dilution rather than a vote of confidence in free cash flow. Meanwhile, operating income of $16.7 million and net income of $9.6 million sit against assets of $178.3 million, leaving a balance sheet that reads like a lab bench-functional but visibly stressed.

If you’re hunting for a chart, the evidence rail doesn’t supply one, so treat this as a fundamentals-first dispatch. The company’s products are real, its customers are real, and its filings are real; the tension is whether the operating cash is keeping pace with the polished catalogue. Watch the inventory turns and the board’s next equity grants; those two dials will tell you more about dilution risk than any glossy brochure.

The company’s website showcases casework, fume hoods, and epoxy resin countertops as core offerings, with product pages explicitly stating that the steel casework and fume hoods are designed to protect lab workers and that the countertops are manufactured in the USA. The imagery is crisp, the claims are bold, and the numbers are polite reminders that the factory floor still has to pay for the steel and the resin. (source: Kewaunee official product pages and 10-K, https://kewaunee.com/products/, https://www.sec.gov/Archives/edgar/data/55529/000095012326006596/kequ-20260430.htm)

What remains unproven is whether the company can convert its $282 million revenue stream into a cash pile that matches its marketing polish. The equity plan approved in July 2026, the thin R&D budget, and the $2.3 million inventory drawdown all hint at a business optimising optics over cash conversion. If the next 10-K shows operating cash comfortably above $20 million and inventory turns accelerating, the story flips from tightrope to steady march. Until then, the catalogue stays glossier than the cash.

Evidence still lacks any analyst commentary, valuation commentary, or macro pressure; the file is built from SEC filings, the company website, and the official product rails. If the rail adds conference-call transcripts, customer concentration data, or order backlog disclosures, the next story will tighten its aperture accordingly.